Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus + lactobacillus plantarum
- Development stage
- Unknown
- Lead developer
- Junlebao Dairy
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Lactobacillus rhamnosus + Lactobacillus plantarum** is a combination of two probiotic strains commonly administered orally as a dietary supplement or therapeutic adjunct. Both species are lactic acid bacteria naturally present in the human gut and mucosal surfaces. This combination is intended to support gut flora integrity, enhance colonization of beneficial bacteria, and modulate host immune responses. Mechanistically, they act by competitive exclusion of pathogens, restoration of microbial balance after antibiotic use, potential modulation of mucosal immunity, and production of metabolites (e.g., lactic acid) that lower gut pH, inhibiting harmful microbes. Clinical studies have evaluated this combination for prevention of urinary tract infections, support of infant intestinal colonization, reduction in antibiotic-associated diarrhea, and potential benefits in oral health and prevention of periodontal disease[1][3][4].
02
Targets
Shigella spp. (Shigella species)TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on lactobacillus rhamnosus + lactobacillus plantarum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus + lactobacillus plantarum.